Jan Cerny to Busulfan
This is a "connection" page, showing publications Jan Cerny has written about Busulfan.
Connection Strength
0.349
-
McCune JS, Wang T, Bo-Subait K, Aljurf M, Beitinjaneh A, Bubalo J, Cahn JY, Cerny J, Chhabra S, Cumpston A, Dupuis LL, Lazarus HM, Marks DI, Maziarz RT, Norkin M, Prestidge T, Mineishi S, Krem MM, Pasquini M, Martin PJ. Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. Biol Blood Marrow Transplant. 2019 07; 25(7):1424-1431.
Score: 0.160
-
Murthy GSG, Kim S, Estrada-Merly N, Abid MB, Aljurf M, Assal A, Badar T, Badawy SM, Ballen K, Beitinjaneh A, Cerny J, Chhabra S, DeFilipp Z, Dholaria B, Perez MAD, Farhan S, Freytes CO, Gale RP, Ganguly S, Gupta V, Grunwald MR, Hamad N, Hildebrandt GC, Inamoto Y, Jain T, Jamy O, Juckett M, Kalaycio M, Krem MM, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Ort? G, Patel SS, Van der Poel M, Rizzieri DA, Savani BN, Seo S, Solh M, Verdonck LF, Wirk B, Yared JA, Nakamura R, Oran B, Scott B, Saber W. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023 07 01; 108(7):1900-1908.
Score: 0.054
-
Oran B, Ahn KW, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, Wirk B, Scott BL, Savani BN, Bredeson C, Weisdorf D, Marks DI, Rizzieri D, Copelan E, Hildebrandt GC, Hale GA, Murthy HS, Lazarus HM, Cerny J, Liesveld JL, Yared JA, Yves-Cahn J, Szer J, Verdonck LF, Aljurf M, van der Poel M, Litzow M, Kalaycio M, Grunwald MR, Diaz MA, Sabloff M, Kharfan-Dabaja MA, Majhail NS, Farhadfar N, Reshef R, Olsson RF, Gale RP, Nakamura R, Seo S, Chhabra S, Hashmi S, Farhan S, Ganguly S, Nathan S, Nishihori T, Jain T, Agrawal V, Bacher U, Popat U, Saber W. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplant Cell Ther. 2021 11; 27(11):921.e1-921.e10.
Score: 0.047
-
Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valc?rcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020 07 14; 4(13):3180-3190.
Score: 0.044
-
Ahmed S, Ghosh N, Ahn KW, Khanal M, Litovich C, Mussetti A, Chhabra S, Cairo M, Mei M, William B, Nathan S, Bejanyan N, Olsson RF, Dahi PB, van der Poel M, Steinberg A, Kanakry J, Cerny J, Farooq U, Seo S, Kharfan-Dabaja MA, Sureda A, Fenske TS, Hamadani M. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. Br J Haematol. 2020 08; 190(4):573-582.
Score: 0.043